Securities abbreviation: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) securities code: Jiangsu Kanion Pharmaceutical Co.Ltd(600557) Announcement No.: 2022012 Jiangsu Kanion Pharmaceutical Co.Ltd(600557)
With regard to the announcement on the appointment of senior managers and the change of securities affairs representatives, the board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibilities for the authenticity, accuracy and completeness of its contents. March 2, 2021, Jiangsu Kanion Pharmaceutical Co.Ltd(600557) (hereinafter referred to as “the company”) the 14th meeting of the 7th board of directors deliberated and approved the proposal on appointing Mr. Gao Haixin as the deputy general manager of the company, the proposal on appointing Mr. Wang chuanlei as the deputy general manager of the company, the proposal on appointing Mr. Pan Yu as the deputy general manager of the company and the proposal on appointing Mr. Xiao Anliang as the chief financial officer of the company Proposal on appointing Mr. Qiu Hongtao as the Secretary of the board of directors of the company. The details of the appointment of senior managers by the board of directors are hereby announced as follows:
1、 Appointment of senior managers
According to the relevant provisions of the company law and the articles of association, the nomination of Mr. Yang Yongchun, the general manager of the company, and the review of the nomination committee of the board of directors, the board of directors agreed to appoint Mr. Gao Haixin, Mr. Wang chuanlei and Mr. Pan Yu as the deputy general managers of the company, and agreed to appoint Mr. Xiao Anliang as the chief financial officer of the company to be responsible for the financial work of the company, The term of office starts from the date of deliberation and approval by the board of directors to the expiration of the current board of directors. The resumes of Mr. Gao Haixin, Mr. Wang chuanlei, Mr. Pan Yu and Mr. Xiao Anliang are detailed in the annex.
In accordance with the relevant provisions of the company law, the Listing Rules of Shanghai Stock Exchange and the articles of association, Mr. Xiao Wei, the chairman of the company, nominated and reviewed by the nomination committee of the board of directors. After deliberation, the board of directors agreed to appoint Mr. Qiu Hongtao as the Secretary of the board of directors of the company. The term of office is from the date of deliberation and approval of the board of directors to the expiration of the current board of directors. See the attachment for the resume of Mr. Qiu Hongtao.
Mr. Qiu Hongtao has obtained the qualification certificate of the Secretary of the board of directors and participated in the follow-up training of the Secretary of the board of directors organized by Shanghai Stock Exchange on time. His qualification has been reviewed by Shanghai Stock Exchange and has no objection.
2、 Change of securities affairs representative
Mr. Qiu Hongtao, the former securities affairs representative, no longer holds the position of securities affairs representative of the company due to work adjustment. In accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange and the working system of the Secretary of the board of directors, Ms. Chen Yanxi is appointed as the securities affairs representative of the company to assist the Secretary of the board of directors, The term of office starts from the date of deliberation and approval by the board of directors to the expiration of the current board of directors. Ms. Chen Yanxi has obtained the qualification certificate of secretary of the board of directors of the stock exchange. See the attachment for her resume.
3、 Opinions of independent directors
The nomination, deliberation and voting procedures for the appointment of senior managers are legal and effective, in line with the relevant provisions of the company law and the articles of association. According to the personal resume and working ability of the senior managers appointed at the meeting, we believe that the senior managers appointed at the meeting have the conditions suitable for their exercise of their functions and powers, There is no circumstance that Article 146 of the company law may not serve as senior managers of the company, and there is no circumstance that they are punished by the CSRC and other relevant departments and the stock exchange. Therefore, we agree that the board of directors shall appoint Mr. Gao Haixin, Mr. Wang chuanlei and Mr. Pan Yu as the deputy general manager of the company, Mr. Xiao Anliang as the chief financial officer of the company to be responsible for the financial work of the company, and Mr. Qiu Hongtao as the Secretary of the board of directors of the company. The term of office shall be from the date of deliberation and approval of the board of directors to the expiration of this board of directors. It is hereby announced.
Jiangsu Kanion Pharmaceutical Co.Ltd(600557) board of directors March 3, 2022
enclosure:
resume
Gao Haixin, male, born in May 1988, has a doctoral degree, engineer (major in petrochemical industry), member of the Communist Party of China, Chinese nationality and no permanent right of residence abroad. He is now the Secretary of the Party committee and the general manager of the production and sales department of Jiangsu company. He joined the company in 2014.
Wang chuanlei, male, born in February 1975, bachelor degree, EMBA, Chinese nationality, without permanent residency abroad. Since 1998, he has successively served as the sales representative, provincial manager, regional manager and sales director of SmithKline Bicheng (China) Co., Ltd., Shanghai Schering plough Pharmaceutical Co., Ltd. and Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) (Beijing) biopharmaceutical Co., Ltd. He joined the company in 2016 and once served as the sales director of the business department of eusegin (“ginkgo diterpene glucosamine injection” for short), and now he is the head of the sales system investment promotion agent, retail and the third terminal business.
Pan Yu, male, born in June 1971, bachelor degree, non party personage, Chinese nationality, without overseas permanent residency. He has successively held management positions related to marketing in Xi’an Janssen Pharmaceutical Co., Ltd., Sanofi Aventis Pharmaceutical Co., Ltd., Pfizer Investment Co., Ltd. and Weiyan medical technology (Beijing) Co., Ltd. He joined the company in July 2021 and is now the head of the company’s market development center and vice president of Jiangsu Kanion Pharmaceutical Co.Ltd(600557) modern Chinese Medicine Research Institute.
Xiao Anliang, male, born in August 1986, bachelor degree, MBA, intermediate accountant, member of the Communist Party of China, Chinese nationality, without permanent residence abroad. He joined the company in 2010 and successively served as the manager of the production cost department and the manager of the marketing management department of the company. Now he is the manager of the financial department of the company.
Qiu Hongtao, male, born in October 1974, college degree, Chinese nationality, without permanent residency abroad. Since October 2002, he has been in charge of securities affairs in Jilin Paper Co., Ltd. Suning Universal Co.Ltd(000718) (securities code: Suning Universal Co.Ltd(000718) ) and daoyoudao (Beijing) Technology Co., Ltd. He joined the company in August 2015 and is now the manager of the company’s securities management center, the manager of the investment department and the representative of securities affairs. Chen Yanxi, female, born in March 1987, bachelor degree, assistant accountant, CPC member, Chinese nationality, without permanent residency abroad. He joined the company in July 2009 and once served as the financial director of Kangsheng pharmaceutical, a subsidiary, and the deputy manager of the company’s securities affairs department. Now he is the manager of the securities affairs department.
As of the date of this announcement, none of the above-mentioned persons held shares of the company; In the past 12 months, it has no relationship with the directors, supervisors, senior managers, actual controllers and shareholders holding more than 5% of the company; Nor has he been punished by the China securities regulatory authority and other departments or by the stock exchange, there are no conditions prohibiting him from taking office in the company law, the articles of association and other relevant provisions, and there are no circumstances that he has been determined as a market prohibited person by the CSRC and has not been lifted.
